Soticlestat
Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research[1][2].
Product Specifications
CAS Number
[1429505-03-2]
Product Name Alternative
TAK-935; OV935
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/soticlestat.html
Purity
99.83
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1CCC(CC2=CC=CC=C2)(O)CC1)C3=C(C4=CC=NC=C4)N=CC=C3
Molecular Formula
C23H23N3O2
Molecular Weight
373.45
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1] Krista Eschbach, et al. Stiripentol for the treatment of seizures in Dravet syndrome. Expert Rev Clin Pharmacol. 2019 May;12 (5) :379-388.|[2]Toshiya Nishi, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020 Oct 13;10 (1) :17081.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
